DO-BO

How does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?

Discover the newest episode of MAP, the Market Access Podcast, your go-to podcast for all things Market Access. In todays episode our host Dr. Stefan Walzer dives deep into early market access in commercialization planning, bridging the gap between innovation and market success. Joined by Catherine Bacon, founder of Fingerpost Consulting, the conversation unpacks the critical steps early-stage healthcare companies must take to ensure patient access, maximize funding, and achieve commercial success.

Explore the importance of early market access in commercialization planning. Learn how to align clinical trials, evidence generation, and payer requirements to ensure patient access and commercial success. Whether you’re aiming for a successful exit or launching your own product, this episode is packed with actionable advice to secure your path to market success by 2030 and beyond.

Tune in to the full episode and explore how Market Access 4.0 is transforming healthcare commercialization!

Related

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]